• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用纤维蛋白平板法测定纤溶酶原激活剂时的干扰因素。针对组织纤溶酶原激活剂和尿激酶的不同抑制剂的出现情况。

Interfering factors in the assay of plasminogen activators by the fibrin plate method. Occurrence of different inhibitors against tissue plasminogen activator and urokinase.

作者信息

Wijngaards G

出版信息

Thromb Haemost. 1979 May 25;41(3):590-600.

PMID:111368
Abstract

The assay of plasminogen activator activities on fibrin plates was re-evaluated with special reference to fibrinolysis inhibitors present in samples and in fibrin plates. The nature, action and stability of inhibiting material were studied in tissue with considerable differences in activator and inhibitor contents: human lung, liver and placenta. Extracts were tested for inhibitory capacity against purified human uterine tissue plasminogen activator, urokinase and plasmin of fibrin plates prepared from different grades of fibrinogen and fibrin. The tissue extracts inhibited fibrinolysis on fibrin plates to varying degrees, dependent on the sample medium, the type of fibrin plate and the kind of plasminogen activator. The influence of inhibitors in the sample and in the fibrin plate was partly abolished by the presence of 2 M KSCN in the sample. The procedure for preparing the samples as described by Astrup and Albrechtsen did not completely eliminate the inhibitory action against the added plasminogen activators. Comparison of urokinase inhibition with tissue activator inhibition by the tissue extracts as to the degree of denaturation in the Astrup and Albrechtsen procedure showed that they have much in common. Nevertheless, some differences were found which indicated the possible existence of separate urokinase and tissue activator inhibitors or of different inhibition mechanisms for these plasminogen activators.

摘要

针对样品和纤维蛋白平板中存在的纤溶酶原激活物活性测定,结合纤维蛋白平板上存在的纤溶酶抑制剂进行了重新评估。在激活物和抑制剂含量存在显著差异的组织(人肺、肝和胎盘)中研究了抑制物质的性质、作用和稳定性。对从不同等级的纤维蛋白原和纤维蛋白制备的纤维蛋白平板上的提取物,测试其对纯化的人子宫组织纤溶酶原激活物、尿激酶和纤溶酶的抑制能力。组织提取物对纤维蛋白平板上的纤维蛋白溶解有不同程度的抑制作用,这取决于样品介质、纤维蛋白平板类型和纤溶酶原激活物的种类。样品中2M KSCN的存在部分消除了样品和纤维蛋白平板中抑制剂的影响。Astrup和Albrechtsen所述的样品制备程序并未完全消除对添加的纤溶酶原激活物的抑制作用。通过Astrup和Albrechtsen程序中组织提取物对尿激酶抑制和组织激活物抑制的变性程度比较表明,它们有许多共同之处。然而,也发现了一些差异,这表明可能存在单独的尿激酶和组织激活物抑制剂,或者这些纤溶酶原激活物存在不同的抑制机制。

相似文献

1
Interfering factors in the assay of plasminogen activators by the fibrin plate method. Occurrence of different inhibitors against tissue plasminogen activator and urokinase.用纤维蛋白平板法测定纤溶酶原激活剂时的干扰因素。针对组织纤溶酶原激活剂和尿激酶的不同抑制剂的出现情况。
Thromb Haemost. 1979 May 25;41(3):590-600.
2
Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.健康与疾病中的纤维蛋白溶解:系统性红斑狼疮中的严重异常
J Lab Clin Med. 1984 Dec;104(6):962-76.
3
Human articular cartilage contains an inhibitor of plasminogen activator.人体关节软骨含有纤溶酶原激活物的抑制剂。
J Rheumatol. 1988 Jul;15(7):1138-43.
4
Separation of plasminogen activators from human uterine tissue and a comparison with activators from human urine and porcine tissue.从人子宫组织中分离纤溶酶原激活剂,并与人尿和猪组织中的激活剂进行比较。
Thromb Haemost. 1979 Jun 30;41(4):718-33.
5
Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.由组织型纤溶酶原激活剂的NH2末端区域和尿激酶型纤溶酶原激活剂的COOH末端区域组成的嵌合纤溶酶原激活剂在纯化系统和人血浆中的抑制作用。
Thromb Haemost. 1988 Oct 31;60(2):247-50.
6
Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.采用纤维蛋白和非纤维蛋白检测法测定人肿瘤组织及相邻正常组织中的纤溶酶原激活物含量。
Cancer Res. 1986 Apr;46(4 Pt 1):1788-94.
7
Isolation of peptides with anti-urokinase activity from the human placenta.从人胎盘中分离具有抗尿激酶活性的肽。
Thromb Haemost. 1980 Feb 29;42(5):1411-6.
8
Activities of antiplasmin and antiplasminogen activator in serous middle ear effusions.
Ann Otol Rhinol Laryngol. 1985 May-Jun;94(3):293-6.
9
Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.组织型纤溶酶原激活剂与尿激酶在体外的相对纤维蛋白溶解、纤溶及溶栓特性比较
Thromb Haemost. 1981 Jun 30;45(3):225-9.
10
Plasminogen activator and inhibitor activity in human glioma cells and modulation by sodium butyrate.人胶质瘤细胞中的纤溶酶原激活剂和抑制剂活性以及丁酸钠的调节作用。
Cancer Res. 1988 Jan 15;48(2):291-6.

引用本文的文献

1
Cellular and secreted tumor plasminogen activator: the effects of NaCl.细胞和分泌型肿瘤纤溶酶原激活剂:氯化钠的作用
Experientia. 1986 Apr 15;42(4):433-5. doi: 10.1007/BF02118645.